Key facts
- DaCapo Brainscience’s last known valuation is $42.5M (Jun 2025).
- It has raised $29.5M; the latest was Seed Round ($29.5M) in Jun 2025.
- Notable investors include DNS Capital, AbbVie Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for DaCapo Brainscience
- ·The full record, as it builds
Funding rounds
No funding rounds for DaCapo Brainscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DaCapo Brainscience
Developer of a biotechnology platform designed to create disease-modifying therapies for neurodegenerative disorders. The company harnesses patient-derived data, neuroscience, machine learning, and stem-cell technologies to uncover novel therapeutic targets, enabling patients to access breakthrough treatments for conditions such as Parkinson's disease.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Website
- dacapobrain.com/
- Ownership
- Privately Held (backing)
DaCapo Brainscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DaCapo Brainscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DaCapo Brainscience in its N-PORT filings yet. We sweep new filings monthly.